These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 8478870)

  • 1. A method for achieving consensus on rheumatoid arthritis outcome measures: the OMERACT conference process.
    Fried BJ; Boers M; Baker PR
    J Rheumatol; 1993 Mar; 20(3):548-51. PubMed ID: 8478870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee.
    Goldsmith CH; Boers M; Bombardier C; Tugwell P
    J Rheumatol; 1993 Mar; 20(3):561-5. PubMed ID: 8478874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OMERACT conference questionnaire results. OMERACT Committee.
    Boers M; Tugwell P
    J Rheumatol; 1993 Mar; 20(3):552-4. PubMed ID: 8478871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis--progress at OMERACT 7.
    Kirwan JR; Hewlett SE; Heiberg T; Hughes RA; Carr M; Hehir M; Kvien TK; Minnock P; Newman SP; Quest EM; Taal E; Wale J
    J Rheumatol; 2005 Nov; 32(11):2250-6. PubMed ID: 16265712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction.
    Tugwell P; Boers M
    J Rheumatol; 1993 Mar; 20(3):528-30. PubMed ID: 8478864
    [No Abstract]   [Full Text] [Related]  

  • 6. Endpoints in rheumatoid arthritis.
    Tugwell P; Boers M; Baker P; Wells G; Snider J
    J Rheumatol Suppl; 1994 Oct; 42():2-8. PubMed ID: 7823314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactive conference voting. The OMERACT II Committee. Outcome Measures in Rheumatoid Arthritis Clinical Trial Conference.
    Goldsmith CH; Duku E; Brooks PM; Boers M; Tugwell PS; Baker P
    J Rheumatol; 1995 Jul; 22(7):1420-30. PubMed ID: 7562790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal disease activity for rheumatoid arthritis: a preliminary definition.
    Wells GA; Boers M; Shea B; Brooks PM; Simon LS; Strand CV; Aletaha D; Anderson JJ; Bombardier C; Dougados M; Emery P; Felson DT; Fransen J; Furst DE; Hazes JM; Johnson KR; Kirwan JR; Landewé RB; Lassere MN; Michaud K; Suarez-Almazor M; Silman AJ; Smolen JS; Van der Heijde DM; van Riel PL; Wolfe F; Tugwell PS
    J Rheumatol; 2005 Oct; 32(10):2016-24. PubMed ID: 16206362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
    Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group).
    Bingham CO; Pohl C; Woodworth TG; Hewlett SE; May JE; Rahman MU; Witter JP; Furst DE; Strand CV; Boers M; Alten RE
    J Rheumatol; 2009 Oct; 36(10):2335-41. PubMed ID: 19684147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.
    Maksymowych WP; Landewe R; Boers M; Garnero P; Geusens P; El-Gabalawy H; Heinegard D; Kraus VB; Lohmander S; Matyas J; Saxne T; van der Heijde D
    J Rheumatol; 2007 Mar; 34(3):634-40. PubMed ID: 17343311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes from the Patient Perspective Workshop at OMERACT 6.
    Kirwan J; Heiberg T; Hewlett S; Hughes R; Kvien T; Ahlmèn M; Boers M; Minnock P; Saag K; Shea B; Suarez Almazor M; Taal E
    J Rheumatol; 2003 Apr; 30(4):868-72. PubMed ID: 12672218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.
    Anderson JJ; Bolognese JA; Felson DT
    Arthritis Rheum; 2003 Nov; 48(11):3031-8. PubMed ID: 14613263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OMERACT 7 psoriatic arthritis workshop: synopsis.
    Gladman DD; Strand V; Mease PJ; Antoni C; Nash P; Kavanaugh A
    Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii115-6. PubMed ID: 15708925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: preliminary findings in the generic health OMERACT study. OMERACT/ILAR Task Force on Generic Quality of Life. Life Outcome Measures in Rheumatology. International League of Associations for Rheumatology.
    Wells G; Boers M; Shea B; Tugwell P; Westhovens R; Saurez-Almazor M; Buchbinder R
    J Rheumatol; 1999 Jan; 26(1):217-21. PubMed ID: 9918267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response.
    American College of Rheumatology Committee to Reevaluate Improvement Criteria
    Arthritis Rheum; 2007 Mar; 57(2):193-202. PubMed ID: 17330293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity to change of rheumatoid arthritis clinical trial outcome measures.
    Anderson JJ; Chernoff MC
    J Rheumatol; 1993 Mar; 20(3):535-7. PubMed ID: 8478866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.
    Maetzel A; Tugwell P; Boers M; Guillemin F; Coyle D; Drummond M; Wong JB; Gabriel SE;
    J Rheumatol; 2003 Apr; 30(4):891-6. PubMed ID: 12672224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data.
    Yazici Y; Kautiainen H; Sokka T
    J Rheumatol; 2007 Feb; 34(2):311-5. PubMed ID: 17304656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.
    Pincus T; Amara I; Koch GG
    Arthritis Rheum; 2005 Apr; 52(4):1031-6. PubMed ID: 15818698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.